MedTrace Logo

Resistance Exercise, IL-7 and Immune Phenotypes in Prostate Cancer

NCT07724080 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-07-23

No results posted yet for this study

Summary

Hormone therapy for prostate cancer typically causes significant muscle loss. Skeletal muscle releases Interleukin-7 (IL-7), a signalling protein that supports the production of new immune cells. Therefore, losing muscle during cancer treatment may actively weaken the immune system. The goal of this clinical trial is to investigate if a 12-week supervised resistance exercise (strength training) programme can prevent this muscle loss and increase levels of IL-7.

The main questions it aims to answer are:

* Does a 12-week strength training programme raise resting IL-7 levels and increase newly formed immune cell counts?
* Does a single session of strength training trigger an immediate release of IL-7?
* To what extent do exercise-induced improvements in muscle mass and strength translate into reduced fatigue, better physical function, higher quality of life, and improved cardiometabolic health?
* Is the exercise programme safe and well-tolerated during hormone therapy?

Researchers will compare a Resistance Exercise Group to a Usual Care Group to see the effects of strength training against standard medical care.

Participants will:

* Attend a screening visit to check eligibility.
* Complete baseline assessments, including body composition scans, blood tests, fitness tests, and questionnaires.
* Be randomly assigned to either the exercise group or the usual care group.
* Complete three supervised strength training sessions per week for 12 weeks, if assigned to the exercise group.
* Continue with standard medical care, if assigned to the usual care group.
* Repeat all assessments at the end of the 12 weeks.
* Perform one short exercise session during the final visit, with extra blood samples taken before and after to track immediate changes

Conditions

Interventions

OTHER

Supervised Resistance Exercise Programme

A 12-week, supervised resistance training programme delivered in small groups in a gym setting. Participants will train 3 times per week on non-consecutive days, with sessions lasting 45-60 minutes. The programme targets all major muscle groups, with volume and intensity gradually increasing throughout the intervention period.

Sponsors & Collaborators

  • Royal United Hospitals Bath NHS Foundation Trust

    collaborator OTHER

  • University of Bath

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07724080 on ClinicalTrials.gov